Safety and feasibility of cerebrolysin in treatment of primary intracerebral hemorrhage (CLINCH)-a prospective, randomized, open-label, blinded endpoint pilot trial.
Kobayashi A, Rutkowska K, Gocyla-Dudar K, Chelstowska B, Pozarowszczyk N, Karlinski M · 2025 · Frontiers in neurology; 2025
Study findings
The paper describes a planned randomized, open-label, blinded-endpoint pilot comparing Cerebrolysin plus standard care with standard care alone. It does not report completed trial outcomes.
- Population and setting
- CLINCH protocol: planned enrollment of 88 patients with lobar intracerebral hemorrhage
- Evidence type
- Not classified
- Preparation
- See the original report; formulation details require verification.
- Source language
- eng
- Title source
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
Study limitations
- Planned enrollment is not an observed patient count.
- No efficacy or safety conclusion can be drawn from this protocol.
- Full methods and risk of bias have not been independently assessed.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Indexed record and available abstract checked; full text not reviewed.
Recorded source-check date: 2026-10-07. This date does not imply a completed systematic review.
Citation and original source
Original source: Kobayashi A, Rutkowska K, Gocyla-Dudar K, Chelstowska B, Pozarowszczyk N, Karlinski M. Safety and feasibility of cerebrolysin in treatment of primary intracerebral hemorrhage (CLINCH)-a prospective, randomized, open-label, blinded endpoint pilot trial. Frontiers in neurology; 2025 2025.
Molekul research summary: https://molekul.io/research/cbl-update-41180520. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry